The world's fastest LCMS/MS tandem mass spectrometer
Shimadzu has introduced the LCMS-8040 which combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection.
The world’s fastest LCMS/MS tandem mass spectrometer
Expanded range of ultra-fast, high-sensitivity applicationsShimadzu has introduced the LCMS-8040 which combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection.A five-fold increase in sensitivity (reserpine, S/N ratio) has been achieved in comparison to the LCMS-8030 model by improving ion focusing and minimizing ion losses between multi-pole lenses.
The fastest scan speed of 15,000 u/s and the fastest polarity switching time of 15 msec, already known from the LCMS-8030, expand in combination with the higher sensitivity the potential range of LC/MS/MS applications. The LCMS-8040 achieves multiple reaction monitoring (MRM) transition speeds of up to 555 MRMs per second utilizing UFsweeper II collision cell technology. UFsweeper II features high-speed ion transport technology that maintains sensitivity and suppresses crosstalk, even for high-speed or simultaneous multi-component analyses.
LabSolutions LCMS software offers a variety of data processing features, including a Quantitation Browser which processes multiple analytes, and a Data Browser which allows users to analyze and compare multiple sets of data in the same window.
For more information please visit www.shimadzu.eu.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
